# Incretin Drug > The incretin drug pipeline and how these molecules are designed: GLP-1, GIP and glucagon multi-agonists, amylin combinations, oral small molecules, trial results and what comes next. Drug-development view. Incretin Drug is written by a small editorial team that reads the trial papers, the regulatory filings and the patents, so you do not have to read all of them. We cite everything. We sell no drugs and take no money from the companies that make them. ## Articles - [What Is an Incretin? The Gut Hormones Behind a Drug Revolution](https://incretindrug.com/incretin/): Incretin hormones GLP-1 and GIP link gut to pancreas. This article explains how that signal became a crowded drug field, with trial data and open questions. - [The GLP-1 Pipeline: Every Serious Contender in One Place](https://incretindrug.com/glp-1-pipeline/): A guide to the glp-1 pipeline: how next-generation obesity drugs sort by receptor targets and delivery route, from triple agonists to amylin, GIP and oral pills. - [Tirzepatide: How One Molecule Hits Two Receptors](https://incretindrug.com/tirzepatide/): How tirzepatide, a single peptide acting on both GIP and GLP-1 receptors, compares with GLP-1-only drugs, and why the source of its extra weight loss is unresolved. - [Retatrutide: The Triple Agonist Everyone Is Watching](https://incretindrug.com/retatrutide/): A word-by-word reading of retatrutide's one-line definition, covering the three receptors it targets, the TRIUMPH phase 3 results, and the Lilly-versus-Lilly trial. - [Retatrutide Trial Results, Read Carefully](https://incretindrug.com/retatrutide-trials/): Retatrutide results explained: phase 2 and phase 3 weight loss figures, what 'up to 30.3%' means, inflammation data, and why cross-trial comparisons mislead. - [Tirzepatide vs Retatrutide: Is Adding Glucagon Worth It?](https://incretindrug.com/tirzepatide-vs-retatrutide/): Tirzepatide vs retatrutide: retatrutide posts bigger weight-loss numbers, but they come from different trials. See why TRIUMPH-5 is the comparison that counts. - [When Will Retatrutide Be Available? The Regulatory Path](https://incretindrug.com/when-will-retatrutide-be-available/): When will retatrutide be available? Lilly plans to file for US approval in Q1 2027, and a normal FDA review of 10 to 12 months points to early 2028. - [Triple Agonists: Why Three Receptors Might Beat Two](https://incretindrug.com/triple-agonist/): A triple agonist hits the GLP-1, GIP and glucagon receptors with one peptide. Here is why a blood-sugar hormone is in the design and what the trial data show. - [Why a Weight-Loss Drug Would Add Glucagon, of All Things](https://incretindrug.com/glucagon-receptor-agonism/): A glucagon receptor agonist raises blood sugar yet helps weight loss. Learn how retatrutide, survodutide and mazdutide pair it with GLP-1 and GIP activity. - [The GIP Receptor: Agonist or Antagonist?](https://incretindrug.com/gip-receptor/): A close reading of one sentence on the GIP receptor, where both agonist and antagonist drugs add weight loss to GLP-1 therapy, and what that means. - [Maridebart Cafraglutide: Amgen's Antibody Bet](https://incretindrug.com/maridebart-cafraglutide/): A plain look at maridebart cafraglutide, Amgen's GIP-blocking antibody with GLP-1 peptides attached, and why it adds weight loss where tirzepatide does too. - [Survodutide: The GLP-1/Glucagon Dual Aimed at the Liver](https://incretindrug.com/survodutide/): Survodutide is a GLP-1 and glucagon dual agonist aimed at obesity and fatty liver. See why the design is odd, what the data show, and what is missing. - [CagriSema: Pairing Semaglutide With Amylin](https://incretindrug.com/cagrisema/): CagriSema reached 22.7% weight loss in REDEFINE 1, but a 0.13-point gap to tirzepatide in a network meta-analysis shaped the market's reception of the result. - [Amycretin: One Molecule, Amylin and GLP-1](https://incretindrug.com/amycretin/): Amycretin is a single peptide hitting GLP-1 and amylin receptors, with 13.1% oral and 24.3% injected weight loss in early trials. See how it compares. - [Amylin: The Other Satiety Hormone](https://incretindrug.com/amylin-analogs/): Amylin is the satiety hormone behind CagriSema and amycretin. See what it does, why drugmakers pair it with GLP-1, and what remains unproven. - [Oral GLP-1s: Pills Made From Small Molecules vs Peptides](https://incretindrug.com/oral-glp-1/): An oral GLP-1 has to survive digestion. See how peptide pills and non-peptide small molecules like orforglipron tackle that, and what Phase 3 results show so far. - [Orforglipron: The Small-Molecule GLP-1 Pill](https://incretindrug.com/orforglipron/): Orforglipron is Lilly's oral non-peptide GLP-1 drug. See how a small molecule bends the receptor like the hormone does, and what Phase 3 showed. - [The Wegovy Pill: How Oral Semaglutide Works](https://incretindrug.com/wegovy-pill/): The Wegovy pill is oral semaglutide with an absorption enhancer. Learn why its 50 mg dose dwarfs the 2.4 mg shot and what trials show for weight loss. - ['GLP-3' Is Not a Hormone: What People Mean When They Say It](https://incretindrug.com/glp-3/): GLP-3 is a nickname, not a hormone or drug class. Here is how retatrutide's three receptors, search habits and naming shortcuts produced the label. - [Half-Life Engineering: How Incretin Drugs Went From Hours to Weeks](https://incretindrug.com/incretin-half-life-engineering/): Retatrutide half life: the sources give no figure, but weekly dosing in trials shows why the drug must last. See how peptides are engineered to persist. ## Tools - [The Incretin Pipeline Scorecard](https://incretindrug.com/scorecard/): Every major next-generation incretin molecule in one table: receptor targets, route, half-life, phase, best published weight result and the open question, kept current as the research moves. ## Listen - [Next-Gen Incretins: Beyond GLP-1](https://incretindrug.com/#listen): 30 minutes. A narrated research briefing from the Incretin Drug editors, with every source checked. ## Optional - [About](https://incretindrug.com/about/) - [Sitemap](https://incretindrug.com/sitemap.xml)